세계의 페길화 의약품 시장 : 분자, 용도, 유통 채널, 지역별(-2035년)

The Global Pegylated Drugs Market is expected to hit USD 26,497.52 million by 2035, registering a CAGR of 5.17% during the forecast period. PEGylation is the process in which one or more PEG molecules are linked to drugs to make them more stable, more soluble, and their duration in the body is increased while immune reactions are lowered. These advantages result in fewer side effects, better patient compliance, and more extensive use of advanced biopharmaceuticals such as protein therapies and monoclonal antibodies.

PEGylation-Enabled Biologics as the Core Market Driver

Ongoing biologics innovations that have been improved by the advanced methods of PEGylation are the most overwhelming factor driving the PEGylated drugs market. PEGylation is the process that increases the therapeutic performance of biomolecules, can uptake more easily, mainly due to decreased immune reactions. Hence, this technique is a requisite for advanced biologic drug development. These features are the main reasons behind the huge R&D spending and the extended application of PEGylated therapies in chronic and hard-to-treat diseases.

Detailed Sub-Segment Summary

Molecule

• Protein & Peptide: Improves therapeutic targeting and durability.

Enzyme: Provides essential support for metabolic repair.

Aptamer: Precision molecules enhancing targeted treatment delivery.

• Small Molecular Drugs: Versatile agents with rapid therapeutic impact.
• Lipid Nanoparticles: Cutting-edge systems for drug encapsulation.
• Liposomes: Safe carriers offering effective drug release.

Application

• Oncology: Advances cancer treatment through targeted options.
• Neurology: Addresses complex disorders of the nervous system.
• Autoimmune Diseases: Helps balance immune system overactivity.
• Haematology: Enhances care for blood-related medical conditions.
• Others: Encompasses various emerging treatment areas.

Distribution Channel

• Hospital Pharmacy: Central hub for specialized clinical therapies.
• Online Pharmacy: Expands accessibility to prescription medications.
• Retail Pharmacy: Broad distribution for general pharmaceutical needs.

Regional Analysis

The global PEGylated drugs market is expanding at a relatively consistent pace. North America accounts for the largest share due to the major drug approvals and technological advancements, while Europe is growing through robust R&D and high prevalence of chronic diseases. Asia-Pacific stands out as the quickly developing region thanks to the rising cancer cases, aging populations, and regulatory support, whereas the Rest of the World is recording moderate growth because of improving healthcare systems and growing biologics adoption.

Strategic Market Restraints

The market is still debating high production costs, complicated regulatory processes, and possible side effects of the drugs, although it is driven by strong factors. The obstacles slow down product development and increase the commercialization period. The problems must be solved in order to keep up with the market pace.

Key Report Attributes

• Market Size 2024: USD 15,181.26 Million
• Market Size 2035: USD 26,497.52 Million
• CAGR (2025-2035): 5.17%
• Base Year: 2024
• Market Forecast Period: 2025-2035

Market Segmentation Growth

• By Molecule: Macromolecular Drugs - 5.94%, Small Molecular Drugs - 2.87%.
• By Application: Oncology - 7.73%, Neurology - 4.72%.
• By Distribution Channel: Hospital Pharmacy - 4.05%, Online Pharmacy - 7.16%.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TYPE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES
  • 4.2.2 ADVANCEMENTS IN BIOLOGICS
  • 4.2.3 RECENTLY APPROVED PEGYLATED DRUGS
• 4.3 RESTRAINTS
  • 4.3.1 HIGH PRODUCTION COSTS
  • 4.3.2 REGULATORY HURDLES
  • 4.3.3 POTENTIAL SIDE EFFECTS
• 4.4 OPPORTUNITY
  • 4.4.1 EMERGING MARKETS
  • 4.4.2 INNOVATIVE DRUG DELIVERY SYSTEMS
  • 4.4.3 PERSONALIZED MEDICINE

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 IMPACT OF COVID-19 ON THE GLOBAL PEGYLATED DRUGS MARKET
• 5.3 QUALITATIVE ANALYSIS ON ANTI-PEG ANTIBODIES AND IMPACT ON PEGYLATED DRUGS

6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE

• 6.1 OVERVIEW
• 6.2 MACROMOLECULAR DRUGS
  • 6.2.1 PROTEIN AND PEPTIDE
  • 6.2.2 ENZYME
  • 6.2.3 APTAMER
• 6.3 SMALL MOLECULAR DRUGS
• 6.4 LIPID NANOPARTICLES (LNP) AND LIPOSOMES

7 GLOBAL PEGYLATED DRUGS MARKET, BY APPLICATION

• 7.1 OVERVIEW
• 7.2 ONCOLOGY
• 7.3 NEUROLOGY
• 7.4 AUTOIMMUNE DISEASES
• 7.5 HAEMATOLOGY
• 7.6 OTHERS

8 GLOBAL PEGYLATED DRUGS MARKET, BY DISTRIBUTION CAHNNEL

• 8.1 OVERVIEW
• 8.2 HOSPITAL PHARMACY
• 8.3 ONLINE PHARMACY
• 8.4 RETAIL PHARMACY

9 GLOBAL PEGYLATED DRUGS MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 AUSTRALIA
  • 9.4.5 SOUTH KOREA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST & AFRICA
  • 9.5.2 SOUTH AMERICA
    • 9.5.2.1 BRAZIL
    • 9.5.2.2 MEXICO
    • 9.5.2.3 ARGENTINA
    • 9.5.2.4 REST OF SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MARKET SHARE ANALYSIS, 2024
• 10.3 COMPETITOR DASHBOARD
• 10.4 PUBLIC PLAYERS STOCK SUMMARY
• 10.5 CMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT APPROVAL
  • 10.6.2 PRODUCT EXPANSION
  • 10.6.3 APPROVAL DENIED
  • 10.6.4 PRODUCT DISCONTINUATION
  • 10.6.5 AGREEMENT/ACQUISITION
  • 10.6.6 CLINICAL TRIAL FINDINGS

11 COMPANY PROFILES

• 11.1 AMGEN INC.
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 PFIZER INC.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 BIOGEN
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 KEY STRATEGIES
• 11.4 BAYER AG
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGY
• 11.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCT OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 NOVO NORDISK A/S
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 SANDOZ GROUP AG
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 KEY STRATEGIES
• 11.8 ASTRAZENECA
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 KEY STRATEGIES
• 11.9 COHERUS BIOSCIENCES, INC.
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 F. HOFFMANN-LA ROCHE LTD.
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 SWOT ANALYSIS
  • 11.10.6 KEY STRATEGIES
• 11.11 JOHNSON & JOHNSON INC.
  • 11.11.1 COMPANY OVERVIEW
  • 11.11.2 FINANCIAL OVERVIEW
  • 11.11.3 PRODUCTS OFFERED
  • 11.11.4 KEY DEVELOPMENTS
  • 11.11.5 SWOT ANALYSIS
  • 11.11.6 KEY STRATEGIES
• 11.12 ALNYLAM PHARMACEUTICALS, INC.
  • 11.12.1 COMPANY OVERVIEW
  • 11.12.2 FINANCIAL OVERVIEW
  • 11.12.3 PRODUCTS OFFERED
  • 11.12.4 KEY DEVELOPMENTS
  • 11.12.5 KEY STRATEGIES
• 11.13 LES LABORATOIRES SERVIER
  • 11.13.1 COMPANY OVERVIEW
  • 11.13.2 FINANCIAL OVERVIEW
  • 11.13.3 PRODUCT OFFERED
  • 11.13.4 KEY DEVELOPMENTS
  • 11.13.5 KEY STRATEGIES

12 DATA CITATIONS